OpenAI Researcher Miles Wang Targets Drug Discovery Startup

The proposed funding round reportedly features Lightspeed as a lead investor, though discussions remain fluid and subject to change. Wang has disputed these specific figures and the characterization of his venture, though he has not provided alternative details. Should the project move forward, it would join a competitive landscape of AI-focused biotechnology firms.

Investors are increasingly pouring capital into the intersection of machine learning and life sciences. Chai Discovery recently secured $400 million at a $3.8 billion valuation, while Google DeepMind spinout Isomorphic Labs raised $2.1 billion in May. Wang’s startup is expected to focus on identifying new applications for existing pharmaceutical compounds, including those that previously failed in clinical trials, to shorten the pathway to market.

Wang, who joined OpenAI in 2024 after leaving Harvard, previously co-authored research on automating scientific discovery. His move reflects a broader trend of high-profile AI researchers transitioning from foundational model labs to specialized industry applications, often with significant backing from venture capital firms eager to capture the next breakthrough in drug efficacy.